New drug cocktail takes aim at resistant lung cancer
NCT ID NCT04227028
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This early-phase trial is testing whether combining two drugs—brigatinib and bevacizumab—can help people with a specific kind of lung cancer (ALK-positive non-small cell lung cancer) whose cancer has gotten worse despite previous ALK-targeted therapy. The study involves just 5 participants and focuses mainly on safety and finding the best dose. Researchers hope the combination might block tumor growth more effectively than either drug alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brigatinib and bevacizumab
What this could lead to
If it works, this could point toward a new combination treatment for ALK-positive lung cancer that has stopped responding to current ALK drugs.
What could go wrong
This is a very early, small Phase 1 trial with only 5 participants, so results may not apply broadly. The combination may cause unexpected side effects or fail to improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.